Chemspace | Building Blocks for Analogs of Atogepant

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Building Blocks for Analogs of Atogepant

26 October 2021

Building Blocks for Analogs of Atogepant

This September, Atogepant (QUILIPTA) received approval by the FDA for the preventive treatment of episodic migraine in adults. Atogepant is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP and its receptors are exhibited in regions of the nervous system associated with migraine physiopathology. Atogepant blocks CGRP within a one dose per day.

It contains 2-aminopiperidin-3-one moiety in its backbone.

We have made a set of Building Blocks, which contain such parts – the perfect start for your research!

Building Blocks for Analogs of Atogepant

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in